Literature DB >> 8651842

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid.

L A García Rodríguez1, B H Stricker, H J Zimmerman.   

Abstract

BACKGROUND: Amoxicillin-clavulanic acid combination-associated hepatitis and jaundice was first identified in 1988. Numerous case reports and case series have been published since then, but there is no precise estimate of this risk.
METHODS: A retrospective cohort study in the United Kingdom to estimate the risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid and compare it with the one of amoxicillin alone. Data were derived from a cohort of 93,433 users of the combination drug amoxicillin-clavulanic acid and 360,333 users of amoxicillin alone who were aged between 10 and 79 years and who were followed up from 1991 through 1992. After reviewing the information on subjects with suspected liver injury that was recorded on computer files, the clinical records of 177 patients from the attending general practitioners were requested.
RESULTS: They were 35 cases of idiopathic acute liver injury. None was fatal. There were 14 cases of acute liver injury among users of amoxicillin alone. The type of liver injury was hepatocellular in half the cases. There were 21 cases of acute liver injury among users of amoxicillin and clavulanic acid together. The type of liver injury was cholestatic in three quarters of the cases. The incidence rates and 95% confidence intervals (CIs) of developing acute liver injury associated with the combination of amoxicillin and clavulanic acid and amoxicillin alone were 1.7 (1.1-2.7) and 0.3 (.02-0.5) per 10 000 prescriptions, respectively. The rate ratios and 95% CIs of acute liver injury for amoxicillin and clavulanic acid together compared with amoxicillin alone were 6.3 (3.2-12.7) for all patients and 8.4 (3.6-20.8) for patients presenting with jaundice. Among users of amoxicillin and clavulanic acid together, the risk of developing acute liver injury was more than 3 times greater after a course of 2 or more consecutive prescriptions than after a single course of therapy. The risk also increased with age among users of amoxicillin and clavulanic acid together. The combination of advancing age and repeated prescriptions resulted in a risk of developing acute liver injury greater than 1 per 1000 users of amoxicillin and clavulanic acid together.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651842     DOI: 10.1001/archinte.1996.00440110099013

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  37 in total

1.  Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid.

Authors:  J P Richardet; A Mallat; E S Zafrani; M Blazquez; J C Bognel; B Campillo
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

2.  Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid.

Authors:  R J Andrade; M I Lucena; M C Fernández; J L Vega; R Camargo
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Drug use for non-hepatic associated conditions in patients with liver cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

4.  Ascertainment of acute liver injury in two European primary care databases.

Authors:  A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

5.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

6.  Incidence of drug-induced liver injury in medical inpatients.

Authors:  Yvonne Meier; Marzia Cavallaro; Malgorzata Roos; Christiane Pauli-Magnus; Gerd Folkers; Peter J Meier; Karin Fattinger
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

7.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Authors:  M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly
Journal:  Gastroenterology       Date:  2011-04-12       Impact factor: 22.682

8.  Hepatobiliary Quiz (Answers)-16 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-12-21

9.  Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries.

Authors:  Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Carlo Giaquinto; Gino Picelli; Alessandro Oteri; Sandra de Bie; Vera E Valkhoff; Martijn J Schuemie; Giampiero Mazzaglia; Claudio Cricelli; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.

Authors:  S-Simona Jakab; A-Brian West; Dennis-M Meighan; Robert S Brown; William-B Hale
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.